This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Erdmann, E. Search for Related Content PubMed Articles by Erdmann, E. Social Bookmarking                   What's this?

The Benefits of Angiotensin Receptor Blockers in Patients with Chronic Heart Failure and Multiple Co-morbidities

Department of Cardiology, University of Cologne, Cologne, Germany, erland.erdmann{at}uni-koeln.de

Chronic heart failure (CHF) is common among the elderly, who typically suffer from multiple co-morbidities.The clinician therefore needs to consider the possibility of interaction between drugs given to treat these underlying conditions and drugs given to treat CHF. Patients who remain symptomatic despite established CHF therapy derive important clinical benefits from the addition of an angiotensin receptor blocker (ARB), irrespective of age, sex, ethnicity and baseline heart failure, as recognised in the recent revision of the European Society of Cardiology guidelines for the treatment of CHF.

Rationalisation of concomitant therapy in accordance with guideline recommendations can help to minimise the potential for adverse effects.

This case report describes an elderly man with CHF and multiple co-morbidities who remained symptomatic despite established therapy.

Key Words: Chronic heart failure • Co-morbidity • Rationalisation • Candesartan

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 2 suppl, S11-S12 (2005)
DOI: 10.1177/14703203050060020401


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?